Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24478695 | 0.92 | EIF4A3 (0.39) | SCN10AMAPTTHRB | |
| SCHEMBL5526838 | 0.80 | MAPT (0.42) | SCN10AMAPTHTR1D | |
| SCHEMBL19954972 | 0.78 | KDM4E (0.36) | LOXL2MAPTTHRB | |
| SCHEMBL19308817 | 0.75 | KDM4E (0.37) | SCN10AMAPTKDM5B | |
| SCHEMBL18430215 | 0.74 | SCN10A (0.42) | SCN10AMAPT | |
| SCHEMBL26364497 | 0.74 | IDH1 (0.32) | IDH1 | |
| SCHEMBL21524642 | 0.73 | EIF4A3 (0.42) | SCN10AMAPTTHRBHTR1D | |
| SCHEMBL19440430 | 0.72 | NR3C1 (0.37) | LOXL2MAPT | |
| SCHEMBL19788242 | 0.72 | METTL3 (0.32) | KDM5B | |
| SCHEMBL21240033 | 0.72 | HTT (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | IDH1 1532/4885SCN10A 1867/4885LOXL2 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.